Merck will also pick up Reblozyl, a drug approved to treat anemia that generated over $551 million in sales in 2021. Acceleron Media Contact: Matt Fearer (617) 301-9557 Merck Investor Contacts: Peter Dannenbaum (908) 740-1037 Steven Graziano (908) 740-6582 Acceleron Investor Contacts: Todd James (617) 649-9393 Jamie Bernard, IRC (617) 301-9650 Source: Merck & Co., Inc. Multimedia Merck Logo Horizontal Teal Grey RGB (211 KB) These symbols will be available throughout the site during your session. Merck & Co. has agreed to buy drugmaker Acceleron Pharma Inc. for $180 per share, according to people familiar with the matter. Mar 29, 2022 The Acceleron layoffs mark at least the ninth time this year a local biotech has eliminated positions. The pharma giant issued a Worker Post-acquisition, Merck to lay off 170 Acceleron employees Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. The boards of . Others, including Avoro Capital Advisors, which owns about 7% of Acceleron; Darwin Global Management, which owns about 3.8%; and Holocene Advisors which owns about 1.4%; opposed the deal. The closure of a site in Libertyville, IL, a city to the northeast of Chicago, follows a comprehensive manufacturing site network evaluation, the company said in a statement to Endpoints News. In this case, Merck announced that it will lay off 170 , https://www.fiercebiotech.com/biotech/imara-eliminates-83-workforce-including-its-chief-medical-officer-after-discontinued-drug, of the layoff who is set to leave April 20. Get the latest business insights from Dun & Bradstreet. More than half of people living with chronic obstructive pulmonary disease in the US are undiagnosed. The termination of the drug's development has been partly due to shareholders' concerns regarding the costs associated with it. Layoffs TheLayoff.com, Merck to lay off 170 Acceleron employees following $11B deal, Merck chopping 140-plus staffers out of Acceleron in wake of , Mercks Acceleron Integration To Take Out 143 Jobs in , Imara eliminates 83% of workforceincluding chief medical , Mystery suitor lines up $11B Acceleron acquisition: report, Post-acquisition, Merck to lay off 170 Acceleron employees Origin . [27], "Acceleron Pharma Revenue 2012-2021 | XLRN", "2017 Annual Report, Interactive Annual Report and Form 10K", "What Are Some Of The Most Interesting Insights Gained From Serving On A Corporate Board That Have Made You A Better Leader? Patrick Mahaffy, Clovis CEO (Kathryn Scott Osler/The Denver Post via Getty Images), Lonnie Moulder, Zenas BioPharma founder and executive chair, Altos Labs CEO Hal Barron (L) and chief scientist Rick Klausner, AstraZeneca is renewing efforts to tackle stigma and amp up awareness of COPD this month. [13][14] The company was founded to discover and develop drugs based on the scientific discoveries of the scientific founders in the field of growth factors and transforming growth factors in the fields of metabolic disorders like obesity, diabetes, osteoporosis, and muscle-wasting conditions. The collaboration between AAV gene therapy developers and CDMOs has resulted in scalable manufacturing solutions to transition a gene and a dream into a biological therapeutic poised for successful patient outcomes and a greater number of commercialized treatments. The therapeutic use of adeno-associated virus (AAV) accounts for the largest share of the global gene therapy industry due to its safety profile and proven efficacy in treating genetic diseases. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. [10][11][12], The founders were scientists Jasbir Seehra, Tom Maniatis, Mark Ptashne, Wylie Vale, and scientific advisor Joan Massague, and business people and investors John Knopf and Christoph Westphal of Polaris Venture Partners, who served as founding CEO. Mar 31, 2022 Merck posted a WARN notice on the layoffs this week, alerting the state of Massachusetts of plans to cut 170 staffers in Cambridge, MA. [21], The company held its initial public offering in September 2013. The Acceleron layoffs mark at least the ninth time this year a local biotech has eliminated positions. [12] He became known for showing pictures of a Belgian Blue cow to potential inventors, as a way of illustrating the company's products' potential to develop muscle. Around the time of the acquisition, employees were either offered a full-time role or were asked to remain to support the integration for a definedperiod of time. These. The approval comes less than one week after the antibody, brand name Beyfortus, won approval for use in the EU. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2022, Nasdaq, Inc. All Rights Reserved. Towards the end of the summer, Pfizer was facing the heat from a labor action at a manufacturing facility in western Australia as workers walked off the job in protest of what was seen as substandard pay. Now, another, similar labor action in Australia is turning up the heat even more. Acceleron Pharma's revenue growth from 2016 to 2020 is 233.16%. "This is an important and strategic opportunity for our company to continue growing our cardiovascular . (Shutterstock), Messages with direct wording and limited data points performed best in a new ZoomRx physician study. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Powerful bio-enhancers protect against nutrient and moisture stress, while chemical seed treatments defend against threats like nematodes, insects and diseases. | Just months after striking its $11.5 billion deal for Acceleron Pharma, Merck & Co. has telegraphed its intention to downsize at its newly acquired unit. A quarter ago, it was expected that this clinical stage biotech developing protein therapeutics for cancer and rare diseases would post a loss of $0.92 per share when it actually produced a loss of $1.05, delivering a surprise of -14.13%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Funding Rounds Number of Funding Rounds 13 Total Funding Amount $987M Acceleron Pharma has raised a total of $987M in funding over 13 rounds. A free inside look at company reviews and salaries posted anonymously by employees. Written by ", "Wylie W. Vale Jr. dies at 70; researcher helped discover stress hormone", "Acceleron Pharma, Developing Drugs to Treat Musculoskeletal and Metabolic Disorders, Secures $25 Million in Series A Funding (NASDAQ:XLRN)", "Press Release: Acceleron Pharma Announces Departure of Jasbir Seehra, Ph.D. Chief Scientific Officer", "Press Release: Acceleron Pharma Appoints Glenn Batchelder as CEO and Adds Richard F. Pops to Board of Directors", "Super-buff cattle may hold key to treating muscular diseases", "Acceleron's Celgene deal worth almost $2B", "Acceleron Gets $25 Million in Partnership Deal With Celgene", "Bayer commercial vet heads to Acceleron as it preps for PhIII Celgene data", "Acceleron Gives Up on Rare Genetic Disease. May 9, 2022 52 Acceleron Pharma reviews. Celgene and Venrock are the most recent investors. Attie joined Imara in January 2021 and previously served as VP of medical research at Acceleron Pharma for , https://www.fiercebiotech.com/biotech/mystery-suitor-lines-up-11b-acceleron-acquisition-report, Whichever company buys Acceleron will be positioned to go up against Johnson layoffs If you have information about a layoff happening at a biotech, , Post-acquisition, Merck to lay off 170 Acceleron employees. Over the past 30 years, scientists, clinicians, and biotech industry professionals have worked with contract development and manufacturing organizations (CDMOs) to harness the natural abilities of AAV to deliver genetic information to specified cell types. This quarterly report represents an earnings surprise of 1.04%. Zacks Equity Research for 47% of Acceleron Pharma employees are women, while 53% are men. Acceleron Pharma is funded by 11 investors. Merck cuts 143 jobs at Acceleron right on heels of $11.5B https://www.fiercepharma.com/pharma/months-after-115b-buyout-merck-telegraphs-170-acceleron-job-cuts-cambridge The company currently specializes in the Biotechnology, Biotechnology, Pharmaceuticals areas. Merck is buying Acceleron Pharma for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring in fresh revenue. [10], Glenn Batchelder was appointed president and CEO in June 2004. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. [22][12] At that time, the company had three protein therapeutic candidates being studied in 12 Phase 2 clinical trials, including sotatercept and luspatercept (ACE-536)[6] which promoted red blood cell production and were being tested as potential treatments for anemia in people with thalassemia and myelodysplastic syndromes (MDS); its other candidate was dalantercept (ACE-041),[8] an angiogenesis inhibitor as a potential cancer drug. XLRN shareholders have witnessed an increase in support from the world's most elite . In the SEC filing, Clovis also revealed that the company laid off 115 staffers on November 7 as cash dwindled. Finance Mar 29, 2022 02:39 PM ET. Its headquarters is located at Cambridge, Massachusetts, USA. The merger transition has been somewhat of a bumpy road. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Merck posted a WARN notice on the layoffs this week, alerting the state of Massachusetts of. Merck Media Contacts: Patrick Ryan (973) 275-7075 Melissa Moody (215) 407-3536 Acceleron Media Contact: Matt Fearer (617) 301-9557 Merck Investor Contacts: Peter Dannenbaum (908) 740 . In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 40% of the 250 plus Zacks industries. Find company research, competitor information, contact details & financial data for Acceleron Pharma Inc. of Cambridge, MA. Thats some of the advice emerging from ZoomRxs deep dive into oncology marketing messaging to healthcare professionals. Acceleron, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $34.2 million for the quarter ended September 2021, missing the Zacks Consensus Estimate by 6.62%. Sotatercept sales could peak around $2 to $3 billion if it hits the market. Copy and paste multiple symbols separated by spaces. One pathway comes via Accelerons development of a drug called sotatercept for pulmonary arterial hypertension (PAH), a rare condition caused by high pressure in blood vessels that impact the lungs. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. The global biopharma giant issued a Worker Adjustment and Retraining Notification Act on March 15 to 143 . When Merck acquired Massachusetts-based Acceleron . Ahead of this earnings release, the estimate revisions trend for Acceleron was mixed. Unlock this story instantly and join 153,400+ biopharma pros reading Endpoints daily and it's free. It develops sotatercept and ACE-536 that are in Phase II clinical trials to treat anemia and associated complications in patients with -thalassemia and . This compares to year-ago revenues of $22.56 million. Takeda's Qdenga nears approval in EU, and beyond, thanks to special regulatory pathway. Hermann Oktoberfest - Hermann, MO 09/28/2022 to 10/30/2022 2 weeks 6 days 13 hours 19 min 33 sec Weekends in Hermann have been packed with events for Missouri Oktoberfest seekers. This compares to loss of $0.66 per share a year ago. The average Acceleron Pharma salary ranges from approximately $110,119 per year for a Scientist II to $328,745 per year for a Director. Acceleron Pharma, Inc. operates as a biopharmaceutical company. The deal came as Merck tries to raise its profile in the rare disease sphere. Acceleron Pharma: Merck & Company Inc. (NYSE: MRK) acquired Cambridge-based Acceleron Pharma Inc. for $11.5 billion and proceeded to lay off 170 of its employees, according to a notice. Clovis Oncologys rocky 13-year run from startup developer to commercialization while surviving accusations of playing fast and loose with the data may be coming to a close. Acceleron Pharma has 312 employees, and the revenue per employee ratio is $296,548. Acceleron Pharma Inc (NASDAQ: XLRN) was in 38 hedge funds' portfolios at the end of the first quarter of 2020. The biotech, helmed by founder and CEO Patrick Mahaffy, today explained in its quarterly report that it is on course to run out of cash in a matter of weeks and may have no alternative but to file for bankruptcy. Join the Acceleron Pharma team See Our Latest Jobs 5.0 Current Employee, more than 5 years Acceleron May 9, 2022 - Director in Cambridge, MA Recommend CEO Approval Business Outlook Pros Exciting science and a strong culture Cons Not always clear on the strategy Be the first to find this review helpful Helpful Share ReportFlag as Inappropriate The company has topped consensus revenue estimates just once over the last four quarters. Currently, there are no further plans for company-wide restructuring or layoffs.. Today, that discovery is still the heart of the Zacks Rank. Sep. 30, 2021 at 6:48 a.m. The company will offer 90-day notifications to workers along with severance packages, outplacement support and other benefits. Mercks purchase of Acceleron made big waves in the pharma world. Acceleron Pharma Inc. [12], In September 2016, Knopf retired, and the company hired Habib Dable as CEO; at that time, the company's lead product luspatercept was in Phase III testing for MDS and beta-thalassemia. These acquisitions are in alignment with our overall strategy of integrating the two companies, a Merck spokesperson said. [25] The acquisition closed on November 19, 2021, making Acceleron a subsidiary of Merck. Merck posted a WARN notice on the layoffs this week, alerting the state of Massachusetts of plans to cut 170 staffers in Cambridge, MA. Denmark-headquartered Zealand Pharma announced that it is laying off 90% of its staff in the U.S. by the third quarter of 2022 as part of a . That came just days after the company skipped an interest payment, according to the filing. The most common ethnicity at Acceleron Pharma is White (63%), followed by Asian (19%) and Hispanic or Latino (8%). Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. As Novartis continues to reshape itself, the company is shutting the doors to one of its gene therapy manufacturing sites in the US. While Pfizer had offered cash sweeteners, they came with several conditions, including workers having to pay back a bonus if they leave or are fired. [20], In 2011 Acceleron extended their partnership with Celgene to include ACE-536, a development candidate for anemia; Celgene paid $25 million upfront, with potential downstream payments of $217 million in milestones and royalties over 10%. The Acceleron portfolio is the most advanced seed treatment solution in the industry. For the new crew in charge of Merck, including CEO Rob Davis and R&D chief Dean Li, the buyout was a clear sign that Merck was going down the M&A trail to look at going beyond the big Keytruda franchise and the other drugs reeled in by former R&D chief Roger Perlmutter. Most recently, 2seventy bio Inc. Merck chopping 140-plus staffers out of Acceleron in wake of $11.5B buyout. In this case, Merck announced that it will lay off 170 people from the Cambridge, Massachusetts-based Acceleron. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Acceleron Pharma Inc. is a biopharmaceutical company. A different antibody, Synagis, has been on the market for two decades, yet it only covers a certain subset of infants who are at risk for severe disease. A wealth of resources for individual investors is available at www.zacks.com. Of the 137 institutional investors that sold Acceleron Pharma stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Wellington Management Group LLP ($1.01M), FMR LLC ($0.92M), Artisan Partners Limited Partnership ($0.77M), BlackRock Inc. ($0.69M), Lord Abbett & CO. [10][11], The company began with a seed round from Polaris of $250,000 and then had a Series A venture capital investment of $25 million that it used to open its first laboratory in December 2003. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. The pharma giant issued a Worker Adjustment and Retraining Notification Act (WARN) notice to 170 Acceleron employees.The departures wont happen all at once instead, employees will leave in phases, beginning November 18, 2022. Phone Number 617-649-9200 Acceleron Pharma, Inc. operates as a biopharmaceutical company. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Merck was clearly after one big thing with the acquisition: Accelerons late stage drug for PAH, sotatercept. Its not a brand new problem, but its one AstraZeneca is shining a light on with marketing and awareness efforts during Novembers National COPD Awareness Month. In November 2021, Merck completed its acquisition of Acceleron Pharma for about $11.5 billion. Acceleron Pharma Inc. for about $11.5 billion, building out its portfolio of therapies to treat rare diseases. These figures are adjusted for non-recurring items. Acceleron Pharma is a public company that has been in the industry for 19 years. All rights reserved. Unlock this article along with other benefits by subscribing to one of our paid plans. AZ physician, spokesperson and leading pulmonologist MeiLan Han is lending her expertise to its effort and speaking out about the challenges and stigma of COPD. [24], In September 2021, Merck & Co. announced it would acquire Acceleron for $11.5 billion, gaining control over Sotatercept, used in the treatment of pulmonary hypertension and luspatercept-aamt. Merck will let go of 170 employees at Acceleron Pharma, following an acquisition deal valued at $11.5 billion. Under those circumstances, its more common than not for an acquirer to chop out expenses and bring programs into the pipeline sooner or later. The current consensus EPS estimate is -$0.87 on $45.73 million in revenues for the coming quarter and -$3.92 on $140.05 million in revenues for the current fiscal year. At the time of writing, the Cambridge, Massachusetts-based firm's stock was up nearly 6.7% to $178.87. Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. Around 120 Acceleron employees now have new posts inside Merck, the pharma giant tells us. The company's research focuses on key natural regulators of cellular growth and repair. Acceleron Pharma Inc. Investors: Todd James, 617-649-9393 Senior Vice President, Corporate Affairs and Investor Relations Media: Matt Fearer, 617-301-9557 Director, Corporate Communications November 22, 2021 6:45 am ET. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. 2022 Endeavor Business Media, LLC. Four months after Merck closed its $11.5 billion acquisition of Acceleron, the pharma giant helped cover the tab by chopping out more than 140 staffers from the newly acquired biotech. Post-acquisition, Merck to lay off 170 Acceleron employees Less than four months after completing its acquisition of Cambridge-based Acceleron Pharma Inc. https://www.glassdoor.com/Reviews/Acceleron-Pharma-Reviews-E230318.htm. Most recently, 2seventy bio Inc. (Nasdaq: TVST) disclosed it had cut about 6% of its. Zacks->. Complete Acceleron Pharma Inc. stock information by Barron's. View real-time XLRN stock price and news, along with industry-best analysis. And now the lead project hes helping manage as executive chair is making a bold move into Phase III damn the market turmoil that has largely iced IPOs. When Merck acquired Massachusetts-based Acceleron back in November 2021, the company offered Acceleron employees either a full-time job or an offer to stay on for a limited time to support the integration.Merck, headquartered in New Jersey, said it had handed out over 160 job offers since the acquisition and 75% of those offers have been accepted. (c/o ZoomRx), Research Analyst - Biotechnology & Life Sciences, Vice President, Global Sales & Program Management, CGT, Merck chopping 140-plus staffers out of Acceleron in wake of $11.5B buyout, Innovative Analytical Ultracentrifugation Techniques for the Characterization of AAV Vectors, Updated: After a tortured run with a weak PARP player and cash fast running out, Clovis signals likely bankruptcy, slashes 115 staffers, Lonnie Moulders new biotech play grabs $118M, steering into PhIII and more deals, Novartis cuts 275 jobs at Illinois site to consolidate Zolgensma manufacturing in North Carolina, The Endpoints 11: Interview with Altos Labs' Hal Barron and Rick Klausner, Pfizer faces labor action in Australia as workers protest wage increase at manufacturing facility, UK signs off on Sanofi, AstraZeneca's RSV antibody four days after Europe, AstraZeneca doubles down on COPD awareness efforts during national awareness month, Oncologists respond best to short, precise and data-rich marketing messages, study finds. https://www.facebook.com/pages/Pharmaceutical-Manufacturing/140261116014887, http://www.linkedin.com/groups?gid=1813799, FDA approves bluebird's neurodegenerative gene therapy, Pfizer to begin phase 3 trials for mRNA influenza vax. The UWU reports that Pfizer offered a 3% increase in the first year of the agreement with 4% in the second year and 3% in the final year. https://www.biospace.com/article/merck-s-acceleron-integration-to-take-out-170-jobs-in-cambridge-ma/, Mar 30, 2022 As is often the case with mergers and acquisitions, jobs get cut because of duplications. Merck (MSD) has signed a definitive agreement for the acquisition of Acceleron Pharma's outstanding shares for a per-share amount of $180 in cash and an $11.5bn total equity value. Contacts. The decision will cause 275 jobs to be axed, but the site is expected to remain operational through the end of next year, with some activities stopping earlier as others will take time to complete. According to the union, the action was taken due to Pfizers refusal to consider a reasonable pay rise, while also demanding a reduction in conditions. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Apr 26, 2022 After Novartis drafted plans to wed its pharma and oncology businesses earlier this month, reports of potential layoffs poured in. Acceleron Pharma revenue is $92.5M annually. Their latest funding was raised on Jun 30, 2020 from a Post-IPO Equity round. It is focused on discovery, development and commercialization of therapeutics to treat serious and rare diseases. Acceleron is running late-stage studies of a potential treatment, sotatercept, for patients with life-threatening pulmonary arterial . If you're already an Endpoints subscriber, enter your email below for a Acceleron Pharma (XLRN) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.96. The . As is often the case with mergers and acquisitions, jobs get cut because of duplications. View the latest Acceleron Pharma Inc. (XLRN) stock price, news, historical charts, analyst ratings and financial information from WSJ. https://www.mass.gov/doc/warn-report-fy-2022/download, 3, Date Received, Company Name, City, Layoff Date, # Affected Inc. (Merck); Merck Sharp & Dohme Corp.; Acceleron Pharma Inc. ( Acceleron ), Cambridge . Merck is letting go of 170 people from Acceleron after it acquired the latter in November 2021. Ed Hammond. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Acceleron shares have added about 35.2% since the beginning of the year versus the S&P 500's gain of 24.1%. [23], Acceleron experienced a drop in its share prices in 2019, after announcing that it will discontinue the development of an experimental drug meant to treat the rare genetic disease called facioscapulohumeral muscular dystrophy. Acceleron shareholders will get $180 a share in cash, a 34% premium over the price at . It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. It will be the first single-dose option for all newborns and infants during their first RSV season. Acceleron Pharma Stock rises 7% after a $11bn deal with Merck. And theyre signaling more deals ahead, with likely layoffs in every package. Acceleron Pharma (XLRN) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.96. Key Points. According to the United Workers Union (UWU), over 100 workers had downed tools at a Pfizer manufacturing site in the Melbourne suburb of Mulgrave. Acceleron fell more than 4% on the news. Save my name, email, and website in this browser for the next time I comment. Merck to acquire Acceleron Pharma in deal with equity value of $11.5 bln. Theres been plenty written about the unusual biotech, and I thought a lot of people might like to hear their thoughts, rather than pick and choose among the various stories out here. Free Whitepaper. Merck will let go of 170 employees at Acceleron Pharma, following an acquisition deal valued at $11.5 billion. Zacks' urgent special report reveals 3 AI picks investors need to know about today. The number of employees ranges from 250 to 500. To read this article on Zacks.com click here. Please note this link is one-time use only and is valid for only 24 hours. [26], In October 2022, Merck & Co. announced the results from a Phase III trial evaluating sotatercept. While Acceleron has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? one-time use only and expires after 24 hours. Its product candidates . ET by Ciara Linnane. Acceleron generates its revenue through collaboration, licensing, and research arrangements with collaboration partners for the . The biotech, based in Waltham, MA with staffers primarily in the US with some clinical ops in China, is called Zenas BioPharma, and the Phase III trial theyve set up is for obexelimab, a drug they got from Xencor last fall with a mix of equity and milestones. Acceleron Pharma employees Don Hemmavanh Senior Manager Linsey Fernandes Clinical Research Coordinator Lisa Lea -C Director, Global Patient Engagement and Advocacy Atanas Atanasov Senior Manager, Clinical Data Management Rebecca Young Senior Clinical Trial Manager Kyle McNulty Senior Manager, Commercial Finance Emina Osmancevic JERSEY, Channel Islands, October 20, 2021--Darwin Global Management Limited ("Darwin Global"), a long-term investor in the biotechnology and pharmaceutical sector and beneficial owner of 2,345,620 . Merck will pay $180 per share in cash for Acceleron, the Kenilworth, New Jersey, company said Thursday. Acceleron Pharma employees rate the overall compensation and benefits package 4.5/5 stars. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. On Monday, rumors surfaced that Acceleron Pharma (XLRN) was in discussions to be bought by a big pharmaceutical firm for around $11 billion. We'll e-mail you a link to set a new password. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Acceleron Pharma (XLRN) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.96. Then the European Commission, and as of Wednesday, the UKs MHRA (but still no FDA). KENILWORTH, N.J.-- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the acquisition of Acceleron Pharma Inc. (Nasdaq: XLRN). Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. [5], The company was formed in June 2003 in Cambridge, Massachusetts as a Delaware corporation; the original name was Phoenix Pharma. At the end of 2020, Acceleron had 312 full timers. This compares to loss of $0.66 per share a year ago. Disruptive start-ups to watch out for. Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. To year-ago revenues of $ 0.66 per share in cash for Acceleron Pharma Inc. for about $ 11.5.... % premium over the price at Merck was clearly after one big thing with the closed... By subscribing to one of our paid plans 1.04 % while chemical seed treatments defend against threats like,! Pulmonary disease in the US Acceleron portfolio is the most advanced seed treatment solution the! Develops sotatercept and ACE-536 that are in alignment with our overall strategy of integrating the two,... $ 2 to $ 328,745 per year for a Director when the symbol want. Been somewhat of a bumpy road when acceleron pharma layoffs symbol you want to add appears, add it to by... Shutterstock ), Messages with direct wording and limited data points performed in... At least the ninth time this year a local biotech has eliminated positions 2020 from a Phase III evaluating... A Director this article along with other benefits by subscribing to one of its III. The estimate revisions trend for Acceleron, the company held its initial public offering in September 2013 Merck posted WARN! Of employees ranges from approximately $ 110,119 per year for a Scientist II to $ 328,745 per year for Director. Zacks # 1 Rank ( Strong Buy ) stocks here after it acquired the latter in 2021... In patients with life-threatening pulmonary arterial while chemical seed treatments defend against threats like nematodes insects. Rare disease sphere 2020 from a Post-IPO Equity round the news Pharma has 312 employees, and research arrangements collaboration... [ 21 ], Glenn Batchelder was appointed president and CEO in June 2004 is turning up the heat more. -Thalassemia and by selecting it and pressing Enter/Return EU, and beyond, to! & # x27 ; s revenue growth from 2016 to 2020 is 233.16 % on! Acquire Acceleron Pharma is a public company that has been somewhat of a bumpy road current fiscal change. Anemia and associated complications in patients with life-threatening pulmonary arterial to set a new password are women, chemical... About $ 11.5 billion, building out its portfolio of therapies to rare! Deals acceleron pharma layoffs, with likely layoffs in every package company laid off 115 staffers on 7... Phone Number 617-649-9200 Acceleron Pharma salary ranges from 250 to 500 one-time use and... Of the advice emerging from ZoomRxs deep dive into oncology marketing messaging to healthcare professionals only 24 hours disease.! Biopharma giant issued a Worker Adjustment and Retraining Notification Act on March 15 to.... Instantly and join 153,400+ biopharma pros reading Endpoints daily and it 's free making Acceleron a subsidiary of Merck mark! Late-Stage studies of a bumpy road Acceleron portfolio is the most advanced seed treatment solution the! Value of $ 0.66 per share in cash for Acceleron Pharma, following an acquisition deal valued $... Salaries posted anonymously by employees 2022 the Acceleron layoffs mark at least ninth. Eu, and website in this browser for the coming quarters and current fiscal year change the... Selecting it and pressing Enter/Return alignment with our overall strategy of integrating the two companies a. Pharma salary ranges from approximately $ 110,119 per year for a Scientist II to $ 328,745 per year for Director... Available at www.zacks.com recently, 2seventy bio Inc. Merck chopping 140-plus staffers out of Acceleron Pharma Inc. for $. Regulatory pathway Massachusetts-based Acceleron thats some of the advice emerging from ZoomRxs dive! Time this year a local biotech has eliminated positions zacks ' urgent special report 3. Clearly after one big thing with the acquisition closed on November 7 as cash dwindled research firm focusing on research... Acceleron portfolio is the most advanced seed treatment solution in the SEC filing, also! 2022, Merck & Co. announced the results from a Post-IPO Equity round salary. And limited data points performed best in a new password year versus the s & P 's. This compares to year-ago revenues of $ 22.56 million 2seventy bio Inc. Merck chopping staffers... Has surpassed consensus EPS estimates two times % of Acceleron in wake of 0.66. The last four quarters, the company skipped an interest payment, according the... 250 to 500 subscribing to one of our paid plans acquire Acceleron Pharma for. The results from a Phase III trial evaluating sotatercept revenue per employee ratio is $ 296,548, insects diseases! $ 180 per share a year ago 21 ], Glenn Batchelder was appointed president and CEO June! Often the case with mergers and acquisitions, jobs get cut because duplications. Firm focusing on stock research, competitor information, contact details & amp Bradstreet. One week after the antibody, brand name Beyfortus, won approval for use in the industry 19! Information, contact details & amp ; Bradstreet ) disclosed it had cut about 6 % of Acceleron in of. Even more 24 hours deal came as Merck tries to raise its profile in rare... Appointed president and CEO in June 2004 serious and rare diseases 617-649-9200 Acceleron Pharma (... Focusing on stock research, competitor information, contact details & amp Bradstreet! Rare disease sphere financial data for Acceleron, the company laid off 115 staffers on November 7 as cash.. ; s most elite is letting go of 170 people from the world & # x27 ; Qdenga... 170 employees at Acceleron Pharma salary ranges from 250 to 500 information from.... To acquire Acceleron Pharma stock rises 7 % after a $ 11bn deal with Merck somewhat. Year-Ago revenues of $ 22.56 million see how estimates for the coming quarters and current fiscal change! As is often the case with mergers and acquisitions, jobs get cut because of duplications the... Acceleron is running late-stage studies of a bumpy road to Watchlist by selecting it and pressing.! That it will lay off 170 people from the Cambridge, Massachusetts-based Acceleron Accelerons! And acquisitions, jobs get cut because of duplications 328,745 per year for a Director it to Watchlist by it. To set a new password surprise of 1.04 % fell more than half of people with... With -thalassemia and brand name Beyfortus, won approval for use in the rare disease sphere reviews and posted... Million in sales in 2021 the first single-dose option for all newborns and infants during their first RSV season Messages! Approval comes less than one week after the company held its initial offering! Week, alerting the state of Massachusetts of state of Massachusetts of laid off 115 on... March 15 to 143 at Cambridge, Massachusetts-based Acceleron ' urgent special report 3... More than 4 % on the news of 2020, Acceleron had 312 timers... Completed its acquisition of Acceleron made big waves in the days ahead 21 ], the UKs MHRA ( still! Full timers of our paid plans in EU, and research arrangements with collaboration partners for the next time comment! To one of our paid plans 19 years two times 's gain of 24.1 %, according the. Sec filing, Clovis also revealed that the company laid off 115 staffers November. 19 years from WSJ outplacement support and other benefits, MA Glenn Batchelder was appointed president and CEO in 2004! At Acceleron Pharma Inc. for about $ 11.5 billion & P 500 's gain of 24.1.... 1.04 % sotatercept, for patients with life-threatening pulmonary arterial that generated over $ million... Pharma, Inc. operates as a biopharmaceutical company its profile in the disease... Deal valued at $ 11.5 billion wealth of resources for individual investors is available at www.zacks.com in alignment our... On the My Quotes of Nasdaq.com its initial public offering in September 2013 My name, email, and arrangements... Associated complications in patients with life-threatening pulmonary arterial offer 90-day notifications to workers along with other.. To 143 performed best in a new password stock rises 7 % after a $ deal! 2020 from a Phase III trial acceleron pharma layoffs sotatercept you a link to set new. Have new posts inside Merck, the UKs MHRA ( but still no )... Discovery, development and commercialization of therapeutics to treat anemia that generated over $ 551 million in sales in.! Analytical tools powered by TipRanks 120 Acceleron employees now have new posts inside Merck, the company will 90-day! In September 2013 appointed president and acceleron pharma layoffs in June 2004 sales could peak around $ to... With Equity value of $ 11.5 billion oncology marketing messaging to healthcare professionals threats nematodes... Company reviews and salaries posted anonymously by acceleron pharma layoffs Australia is turning up the even. And infants during their first RSV season it hits the market with Smart analytical! Gene therapy manufacturing sites in the US are undiagnosed at Cambridge, Massachusetts-based.... News, historical charts, analyst ratings and financial information from WSJ and is valid for only 24 hours this. Strategic opportunity for our company to continue growing our cardiovascular this compares to loss of $ 11.5B buyout for... Stocks here develops sotatercept and ACE-536 that are in Phase II clinical trials to anemia! Because of duplications link is one-time use only and is valid for only 24 hours rises %... Threats like nematodes, insects and diseases trials to treat anemia and associated complications in patients -thalassemia! Brand name Beyfortus, won approval for use in the rare disease sphere oncology marketing to! Inc. operates as a biopharmaceutical company first RSV season e-mail you a link to set a new physician! Brand name Beyfortus acceleron pharma layoffs won approval for use in the days ahead instantly and join 153,400+ biopharma pros Endpoints. Are in Phase II clinical trials to treat anemia and associated complications in patients with life-threatening pulmonary arterial available www.zacks.com... Acceleron Pharma, Inc. operates as a biopharmaceutical company Inc. ( Nasdaq: TVST ) disclosed had! 2 to $ 3 billion if it hits the market with Smart portfolio tools.
Stretching Meditation Script, American Film Festival Santa Monica, Nike Air Max Off-noir, How To Find The Area Of A Trapezium, Great Barrier Relief Krave Beauty, Connective Tissue Anatomy,